Pull up any site activation tracker from the last eighteen months and look at the gap between contract execution and first-patient-in. At most sites, that gap is not explained by budget disputes or slow IRB turnaround in isolation — it is explained by what was in the protocol before the budget got written and before the IRB package got submitted. A coordinator staring at a 140-page protocol with 47 inclusion/exclusion criteria, six scheduled imaging windows, and a PK sampling schedule that requires a four-hour on-site visit is not slow. She is rationally overwhelmed, and the startup clock reflects that reality before a single site qualification visit has been scheduled.
The persistence of protocol complexity is one of those problems the industry has pledged to solve for over a decade while the data moves in the opposite direction. The scientific and organizational forces driving it are real. But the operational tax lands entirely on the site side of the ledger, and most sponsors do not see the invoice.
The Complexity Ratchet
Here is the number that frames everything else: since 2015, the prevalence of clinical trial protocols carrying at least one amendment has risen from 57% to 76%. That is not a marginal drift. That is a structural shift in what the industry considers a functional protocol at activation. Every amendment after first-patient-in is a renegotiation — of the IRB package, the informed consent form, the site contract, the training plan, the EDC build, and in many cases the monitoring visit schedule. Sites absorb all of that labor. The per-amendment cost to a site in coordinator hours, re-consent burden, and query remediation is rarely captured in the original budget, because the amendment was not anticipated in the original budget.
The scientific pressure is real and worth naming. FDA’s Diversity Action Plan requirements, mandated under the Food and Drug Omnibus Reform Act signed in December 2022, have pushed sponsors to broaden eligibility criteria and build stratified enrollment targets into protocols that previously carried narrower populations. The intent is correct. The operational consequence is that a protocol designed to enroll a more diverse population carries more complex screening logic, more extensive baseline assessments, and often more demanding visit schedules — all of which extend the pre-activation period and increase screen failure rates at sites that have not historically served those populations. Sponsors add criteria in response to regulatory expectation. Sites absorb the screening labor that follows.
The organizational pressure is less discussed but equally powerful. Protocol complexity accumulates through internal consensus processes. Medical affairs wants a secondary endpoint. Pharmacovigilance wants an additional safety assessment window. Market access wants subgroup data that requires a stratification variable no one planned for at protocol outline. Each addition is reasonable in isolation. Collectively, they produce a protocol that asks sites to run a logistics operation the original feasibility questionnaire never anticipated. Any coordinator who has worked a Phase II oncology study knows what it looks like when a protocol has been edited by twelve stakeholders and reviewed by none of them together: contradictions in visit windows, PK timepoints that conflict with clinic scheduling hours, and an ECG requirement buried in an appendix that pharmacy finds three weeks after SIV.
The activation data confirms what sites experience daily. A published study found that time-to-site activation showed a statistically significant positive correlation with total protocol complexity score, with a rho of 0.61 at the 75% activation threshold (p = 0.005). A rho of 0.61 is not a weak signal. It means protocol complexity is one of the strongest predictors of how long it takes to get a site running — stronger than most of the operational variables sponsors spend their pre-activation energy managing.
Where the IRB Clock Actually Starts
Sponsors often frame IRB turnaround as an external variable — something that happens to a trial, not something shaped by what the trial contains. That framing does not survive contact with the data.
Research examining IRB review timelines shows a clear relationship between protocol complexity and review duration, with studies requiring full board review — typically those with higher risk profiles or greater procedural complexity — carrying substantially longer approval timelines than expedited reviews. A protocol that triggers full board review because it contains novel procedures, expanded eligibility, or complex stopping rules does not sit in a different queue by accident. The IRB is doing more work because the protocol requires more work. Sponsors who push for aggressive site activation timelines while submitting complex protocols to local IRBs are essentially asking for a faster return on an investment they made larger.
Central IRB adoption has compressed some of this timeline variance for multi-site studies. But central IRB does not eliminate the review burden — it consolidates it. A complex protocol still requires a thorough initial review, and amendments still require amendment submissions. Sites working with local IRBs on complex oncology or CNS protocols routinely carry 60 to 90-day review cycles for full board submissions. When a sponsor’s enrollment plan assumes 45-day activation from contract execution, and the IRB cycle alone consumes 60 days, the math was wrong before the first patient inquiry came in.
That arithmetic problem cascades. A delayed first-patient-in compresses the enrollment window. A compressed enrollment window increases pressure on sites to screen more aggressively. More aggressive screening against a complex I/E criteria set produces more screen failures. Screen failures generate source documentation requirements, partial visit costs, and coordinator time that the budget did not fund. Sites I work with across therapeutic areas routinely absorb two to three screen failures per enrolled patient on complex protocols — costs that compound across a 20-site network into budget shortfalls that trigger renegotiations six months into enrollment.
What Clinops Leaders Are Actually Doing
The FDA’s 2024 final guidance on decentralized clinical trial elements points toward one part of the answer — specifically, redistributing procedural burden away from site visits through remote assessments, home health visits, and local lab options. Decentralized elements do not reduce protocol complexity, but they can reduce the on-site coordination load that complexity generates, which is a meaningful operational distinction when a coordinator is managing five concurrent protocols.
The more durable fix happens earlier — at protocol design, before the I/E criteria have been reviewed by twelve stakeholders and before the visit schedule has been built around pharmacokinetic modeling rather than site scheduling reality. Sites I work with have started requesting protocol feasibility calls that go beyond standard site qualification questions: not just “do you have the patient population” but “can your clinic physically execute this visit schedule, and what does your screen failure rate look like for a comparable I/E profile.” That conversation surfaces operational conflicts before contract execution, which is the only point at which fixing them is free.
On the sponsor side, the operational move is assigning a clinops counterpart — not just a medical monitor — to the protocol design process with explicit authority to flag visit burden, screen failure risk, and IRB review triggers before the protocol reaches final draft. Across our network, the protocols that activate closest to plan are the ones where a site operations lead reviewed the visit schedule against actual clinic hours before it was locked. That review takes two days. Recovering from a 90-day activation delay costs multiples of that in site management time, enrollment pressure, and budget amendments.
The complexity ratchet will not reverse on goodwill alone — the scientific and regulatory pressures driving it are structural. But the sites carrying the operational weight of that complexity do not have to absorb it silently. The activation math is documented. The amendment frequency is documented. The IRB review burden is documented. Sponsors who want sites to run their most complex protocols need to budget for the complexity they wrote into them — and clinops leaders who can show that math, line by line, are the ones who get budgets that reflect operational reality rather than optimistic timelines.
Watch for protocol complexity scoring to move from academic research tool to standard site feasibility practice within the next contract cycle. When sites can hand a sponsor a quantified complexity score with an activation timeline estimate attached to it, the feasibility conversation changes entirely.
References
- MedCity News — “Why Protocol Complexity Keeps Increasing – and How to Fix It”
- Prelude EDC — “Cost of Protocol Amendments, Phase 1: Amendment Prevalence Data 2015–2022”
- PMC/PubMed Central — “Protocol Complexity Score and Time-to-Site Activation: Correlation Analysis”
- PMC/PubMed Central — “IRB Review Timelines and Protocol Complexity: Study of 103 Protocols at a VA Medical Center”
- FDA — Diversity Action Plan Guidance (FDORA, December 2022)
